High Temperatures In Transporting, Storing or Using Ranitidine Leads To Ranitidne Degrading

Recall Lawyer News

The researcher measured more than a 10% increase in NDMA over the amount thought to be safe

Thursday, June 24, 2021 - For more than twenty years, the US Food and Drug Administration has set a limit on the amount of NDMA that can be safely ingested daily at 96 nanograms per tablet. Zantac ranitidine cancer trials could highlight the need for standardized methods of drug testing without exposing the molecule to high heat. Plaintiffs will likely ask Valisure CEO David Light, or one of the top scientists representing the online prescription drug testing pharmacy, to present their findings in court under oath about ranitidine degenerating to form N-nitrosodimethylamine (NDMA) under certain environmental conditions. Valisure testing of ranitidine using the gas chromatography-mass spectrometry (GC-MS) method using high heat found that some samples of ranitidine measure over 3 million nanograms of NDMA per tablet, an alarming amount. Defense attorneys will argue that the gas chromatography-mass spectrometry (GC-MS) method was the cause of the elevation in the carcinogen. Visit Zantac antacid cancer lawsuit to learn more.

News of Zantac ranitidine‘s link to causing cancer made front-page headlines on April 1, 2020, when the FDA recalled ranitidine and banned its sale. Lawsuits began against Sanofi and GalaxoSmithKline that allege taking Zantac regularly for many years caused them to develop stomach, bladder, colon, and other forms of cancer. Plaintiffs accuse Sanofi of covering up what they knew about the ranitidine molecule being unstable. Had plaintiffs known, they would not have taken the heartburn medicine. After about 18 months of studying and evaluating the subject, scientists now agree that ranitidine degenerates to become NDMA when transported or stored at higher than room temperature, or, alarmingly, when taken into the stomach and exposed to the body‘s higher temperatures or nitrates in the stomach.

Plaintiffs suing Sanofi and Chevron may also call Ron Najafi, Ph.D., CEO of Emery Pharma to testify in court on their behalf. Dr. Najafi owns a research laboratory that tested ranitidine using a different method than the one used by Valisure and came up with similar results. Both Valisure and Emery Pharma petitioned the FDA to recall ranitidine for similar cancer fears. According to WebMD, "Najafi, In his research, Najafi found that a 150-milligram tablet of ranitidine, exposed to about 158 degrees, or the temperature a closed car could reach on a hot day, had 106 nanograms of NDMA by day five." Visit https://www.zantacantacidcancerlawsuit.com/ to learn more about Zantac antacid cancer lawsuit.

More than 70,000 Zantac cancer plaintiffs are looking forward to September 30, 2021, the day that U.S.District Judge Robin Rosenberg has designated as Zantac Science Day. Expert witnesses from each side will be permitted to present their stance as to why each ranitidine testing method is better than the other. Please revisit this website for the latest details about the science underlying the Zantac cancer plaintiff‘s allegations and please visit the Valisure blog or LabManager.com. You should speak with a Zantac cancer lawyer if you or a loved one have used Zantac and has been subsequently diagnosed with cancer.